Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 106Carcinoma, Intraductal, Noninfiltrating 6Neoplasms 4Neoplasm Metastasis 3Breast Neoplasms, Male 3Breast Diseases 3Breast Carcinoma In Situ 3Triple Negative Breast Neoplasms 2Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Cancer Metastatic 2Sexual Dysfunction, Physiological 1Seizures 1Multiple Endocrine Neoplasia Type 1 1Locoregional Recurrence 1Lethal Congenital Contracture Syndrome 2 1Inflammatory Breast Neoplasms 1Hypogonadism 1Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Granulosa Cell Ovarian Cancer 1Fallopian Tube Neoplasms 1Erectile Dysfunction 1Epilepsy 1Endometrial Stromal Tumors 1ER+ Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Bulbo-Spinal Atrophy, X-Linked 1Breast Neoplasm Female 1

Interventions

Cyclophosphamide 22Paclitaxel 12Epirubicin 12Doxorubicin 11Trastuzumab 10Docetaxel 10Carboplatin 10Taxes 7Bevacizumab 6pembrolizumab 5Radiotherapy 5Filgrastim 5Albumin-Bound Paclitaxel 5Neoadjuvant Therapy 4130-nm albumin-bound paclitaxel 4Thiotepa 3Tamoxifen 3Panitumumab 3Melphalan 3Lapatinib 3Granulocyte Colony-Stimulating Factor 3Fluorouracil 3Chemotherapy, Adjuvant 3sargramostim 2pertuzumab 2eribulin 2Radiation 2Peripheral Blood Stem Cell Transplantation 2Cisplatin 2Capecitabine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Inflammatory Breast Neoplasms × Anastrozole × Clear all
NCT00398489 2010-11-09

Docetaxel, Epirubicin, and Cyclophosphamide With or Without Trastuzumab in Treating Women With Locally Advanced Breast Cancer That Can Be Removed By Surgery

National Cancer Institute (NCI)

Phase 2 Unknown
94 enrolled
Breast

Breast Neoplasms, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡